medigraphic.com
Instituto Nacional de Salud Pública

2014, Number 3

<< Back Next >>

salud publica mex 2014; 56 (3)

Prevalence of Streptococcus pneumoniae serotype 19A before and after the introduction of the heptavalent conjugate vaccine in Mexico

Echániz-Avilés G, San Román-Álvarez L, Sánchez-Alemán M, Carnalla-Barajas MN, Soto-Noguerón A

Language: Spanish
References: 22
Page: 266-271
PDF size: 290.04 Kb.


ABSTRACT

Objective. To determine the prevalence of S. pneumoniae serotype 19A (Spn19A), before and after the introduction of heptavalent pneumococcal conjugate vaccine (PCV7) in Mexico. Materials and methods. Descriptive study carried out in Mexico with surveillance information of pneumococcal disease, generated from the Sireva network. We performed lineal regression analysis with the proportion of Spn19A by year in two study periods. Data were analyzed using SPSS v.18 software. Results. A total of 1825 S. pneumoniae strains causing infection in pediatric population were recovered in the period 2000-2012, 225/12.3% were Spn19A, and of these, 75/6.3% were isolated in 2000-2008 and 150/23.6% in 2009-2012. There was an increase in antimicrobial resistance post-vaccination for all drugs except vancomycin. Conclusion. It was observed that the frequency of this serotype and antimicrobial resistance increased after the introduction of PCV7.


REFERENCES

  1. Fenoll A, Aguilar L, Vicioso M, Gimenez M, Robledo O, Granizo J. Increase in serotype 19A prevalence and amoxicilin non-susceptibility among paediatric Streptococcus pneumoniae isolates from middle ear fluid in a passive laboratory-based surveillance in Spain, 1997-2009. BMC Infectious Diseases 2011;11:39.

  2. Chibuk T, Robinson J, Hartfield D. Pediatric complicated pneumonia and pneumococcal serotype replacement: trends in hospitalized children pre and post introduction of routine vaccination with pneumococcal conjugate vaccine (PCV7). Rev Eur J Pediatr 2010;169:1123-1128.

  3. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: A metaanalysis. Pediatrics 2009;123;e1103-e1110.

  4. Messina AF, Katz-Gaynor K, Barton T, Ahmad N, Ghaffar F, Rasko D, et al. Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005. Pediatric Infect Dis J 2007;26:461-467.

  5. Parra EL, De la Hoz F, Díaz PL, Sanabria O, Realpe ME, Moreno JE. Changes in Streptococcus pneumoniae serotype distribution in invasive disease and nasopharyngeal carriage after the heptavalent pneumococcal conjugate vaccine introduction in Bogotá, Colombia. Vaccine [consultado: 22 de mayo de 2013]. Disponible: htpp://dx.doi.org/10.1016/j. vaccine.2013.04.074

  6. Measuring impact of Streptococcus pneumoniae and Haemophilus influenzae type b conjugate vaccination. World Health Organization, Immunization, Vaccines and Biologicals. Geneva: WHO, 2012 [consultado: 20 de marzo de 2013]. Disponible en: http://apps.who.int/iris/ bitstream/10665/75835/1/WHO_IVB_12.08_eng.pdf

  7. Pelton SI, Huot H, Finkelstein JA, Bishop CJ, HSU KK, Kellenberg J, et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatric Infect Dis J 2007;26:468-472.

  8. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007;196:1346-1354.

  9. Reinert R, Jacobs M, Kaplan. Pneumococcal disease caused by serotype 19A: Review of the literature and implications for future vaccine development. Vaccine 2010;28:4249-4259.

  10. Jackson LA, Gurtman A, Cleeff M, Jansen KU, Jayawardene D, Devlin C, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine [consultado: 26 de mayo de 2013]. Disponible: http://dx.doi.org/10.1016/j. vaccine.2013.04.085

  11. Poolman J, Frasch C, Nurkka A, Käyhty H, Biemans R, Schuerman L. Impact of the conjugation method on the immunogenicity of Streptococcus pneumoniae serotype 19F polysaccharide in conjugate vaccines. Clin Vaccine Immunol 2011;18:327-336.

  12. Informe Regional de Sireva II, 2010. Datos por país y por grupos de edad sobre las características de los aislamientos de Streptococcus pneumoniae, Haemophilus influenzae y Neisseria meningitidis, en procesos invasores [monografía en internet] Washington,D.C.,2011 [consultado: 25 de septiembre de 2011], Disponible en: http://www.insp.mx/lineas-deinvestigacion/ medicamentos-en-salud-publica/enlaces.html

  13. Chan-Acón W, Abdelnour A, Soley-Gutierrez C, Arguedas-Mohs A. Avances en el desarrollo de las vacunas neumocócicas conjugadas. Acta Med Costarric 2010;52:137-147.

  14. Secretaría de Salud México. Vacunación Universal y Semanas Nacionales de Salud, Lineamientos generales 2008, Centro Nacional para la Salud de la Infancia y Adolescencia. Subsecretaría de Prevención y Promoción de la Salud [consultado: 19 de noviembre de 2012]. Disponible en: http:// salud.chiapas.gob.mx/doc/biblioteca_virtual/manuales_modelos//Manual_ Vacunacion_2008_2009.pdf

  15. Díaz-Ortega JL, Ferreira-Guerrero E, Trejo-Valdivia B, Téllez-Rojo MM, Ferreyra-Reyes L, Hernández-Serrato M, et al. Cobertura de vacunación en niños y adolescentes en México: esquema completo, incompleto y no vacunación. Salud Pub Mex 2013;55 (supl 2):S289-S299.

  16. CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. CLSI document M100-S22. Wayne, PA: Clinical and Laboratory Standards Institute, 2012.

  17. Regiones de origen y destino de la migración México-Estados Unidos [sitio de internet]. México: Conapo [consultado: 17 de marzo de 2013]. Disponible en: www.conapo.gob.mx/work/models/CONAPO/intensidad_ migratoria/pdf/regiones.pdf

  18. Castañeda E, Agudelo C, De Antonio R, Rosselli D, Calderon C, Ortega E. Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010. BMC Infect Dis 2012;12:124.

  19. Kuo CY, Hwang KP, Hsieh TA, Cheng CH, Huang FL, Shen YH, et al. Nasopharyngeal carriage of Streptococcus pneumoniae in Taiwan before and after the introduction of a conjugate vaccine. Vaccine 2011;29:5171-5177.

  20. Weber TJ. Appropriate use of antimicrobial drugs a better prescription is needed. JAMA 2005;294:2354-2356.

  21. Pillai DR, Shahinas D, Buzina A, Pollock RA, Lau R, Khairnar K, et al. Genome-wide dissection of globally emergent multi-drug resistant serotype 19A Streptococcus pneumoniae. BMC Genomics 2009;10:642 doi: 10.1186/1471-2164-10-642.

  22. Dreser A, Wirtz VJ, Corbett KK, Echániz G. Uso de antibióticos en México: revisión de problemas y políticas. Salud Publica Mex 2008;50 (supl 4):S480-S487.




2020     |     www.medigraphic.com